Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow
Blood-based targeted mass spectrometry (MS-MRD) is a sensitive, minimally invasive alternative to measure MM disease activity. The concordance rate between NGS-MRD and MS-MRD in this study was 79%. That is high, considering that the two methods measure different biomarkers, as NGS measures DNA reads from myeloma cells in the bone marrow and MS measures M-protein in the blood. This proof-of-principle study shows that MS-MRD evaluation in blood is a feasible, patient friendly alternative to NGS-MRD assessed on bone marrow.